Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS | Aplastic Anemia & MDS International Foundation
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Clinical Trial: NCT03502668

For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 
  • Drug: ASTX727 LD

    oral decitabine (LD) + cedazuridine (E7727)

    Other Name: oral decitabine (LD) + cedazuridine (E7727)

  • Drug: ASTX727 SD

    oral decitabine (SD) + cedazuridine (E7727)

    Other Name: oral decitabine (SD) + cedazuridine (E7727)

Status: 
Recruiting
Study Date: 
Fri, 07/27/2018 to Thu, 12/31/2020
Bone Marrow Disease(s): 
  • myelodysplastic syndromes (MDS)
Associated Drug(s): 
Intervention: 
Drug: ASTX727 LD oral decitabine (LD) + cedazuridine (E7727) Other Name: oral decitabine (LD) + cedazuridine (E7727) Drug: ASTX727 SD oral decitabine (SD) + cedazuridine (E7727) Other Name: oral decitabine (SD) + cedazuridine (E7727)